TITAN MEDICAL INC.
|
||||
(Registrant)
|
||||
|
||||
Date:
|
November 13, 2018
|
By:
|
/s/ Stephen Randall
|
|
Name:
|
Stephen Randall
|
|||
Title:
|
Chief Financial Officer
|
TITAN MEDICAL INC.
|
||||||||||||
Unaudited Condensed Interim Balance Sheets
|
||||||||||||
As at September 30, 2018 and December 31, 2017
|
||||||||||||
(In U.S. Dollars)
|
||||||||||||
|
Note
|
September 30, 2018
|
December 31, 2017
|
|||||||||
Assets
|
||||||||||||
Current Assets:
|
||||||||||||
Cash and cash equivalents
|
$
|
29,230,819
|
$
|
26,130,493
|
||||||||
Amounts receivable
|
111,150
|
75,151
|
||||||||||
Deposits
|
6
|
4,278,850
|
2,538,434
|
|||||||||
Prepaid expense
|
636,542
|
149,593
|
||||||||||
Total Current Assets
|
$
|
34,257,361
|
$
|
28,893,671
|
||||||||
Furniture and Equipment
|
-
|
6,714
|
||||||||||
Patent Rights
|
3
|
956,360
|
774,225
|
|||||||||
Total Assets
|
$
|
35,213,721
|
$
|
29,674,610
|
||||||||
Liabilities
|
||||||||||||
Current Liabilities:
|
||||||||||||
Accounts payable and accrued liabilities
|
$
|
4,439,591
|
$
|
2,218,352
|
||||||||
Warrant liability
|
2b, 5
|
18,749,143
|
17,849,460
|
|||||||||
Total Liabilities
|
23,188,734
|
20,067,812
|
||||||||||
Shareholders' Equity
|
||||||||||||
Share Capital
|
4a
|
|
170,253,262
|
154,016,519
|
||||||||
Contributed Surplus
|
6,298,717
|
5,146,784
|
||||||||||
Warrants
|
4b
|
|
-
|
741,917
|
||||||||
Deficit
|
(164,526,992
|
)
|
(150,298,422
|
)
|
||||||||
Total Equity
|
12,024,987
|
9,606,798
|
||||||||||
Total liabilities and equity
|
$
|
35,213,721
|
$
|
29,674,610
|
||||||||
Commitments (Note 6)
|
||||||||||||
See notes to financial statements
|
||||||||||||
Approved on behalf of the Board:
|
|||
John E. Barker
|
David McNally
|
||
Chairman
|
President and CEO
|
TITAN MEDICAL INC.
|
||||||||||||||||||||||||
Unaudited Condensed Interim Statement of Shareholders’ Equity and Deficit
|
||||||||||||||||||||||||
For the Periods Ended September 30, 2018 and 2017
|
||||||||||||||||||||||||
(In U.S. Dollars)
|
||||||||||||||||||||||||
Share Capital
|
Share Capital
|
Contributed
|
Total
|
|||||||||||||||||||||
Number
|
Amount
|
Surplus
|
Warrants
|
Deficit
|
Equity
|
|||||||||||||||||||
Balance - December 31, 2016
|
5,550,382
|
$
|
112,742,810
|
$
|
3,707,432
|
$
|
855,800
|
$
|
(116,711,438
|
)
|
$
|
594,604
|
||||||||||||
Issued pursuant to agency agreement
|
2,699,094
|
12,547,765
|
12,547,765
|
|||||||||||||||||||||
Issued private placement
|
563,067
|
1,887,411
|
1,887,411
|
|||||||||||||||||||||
Warrant liability issued during the period
|
(4,661,928
|
)
|
(4,661,928
|
)
|
||||||||||||||||||||
Share issue expense
|
(926,709
|
)
|
(926,709
|
)
|
||||||||||||||||||||
Warrants exercised during the period
|
529,251
|
5,020,022
|
5,020,022
|
|||||||||||||||||||||
Warrants expired during the period
|
113,883
|
(113,883
|
)
|
-
|
||||||||||||||||||||
Stock based compensation
|
1,024,574
|
1,024,574
|
||||||||||||||||||||||
Net and Comprehensive loss for the period
|
(20,757,004
|
)
|
(20,757,004
|
)
|
||||||||||||||||||||
Balance - September 30, 2017
|
9,341,794
|
$
|
126,723,254
|
$
|
4,732,006
|
$
|
741,917
|
$
|
(137,468,442
|
)
|
$
|
(5,271,265
|
)
|
|||||||||||
Balance - December 31, 2017
|
12,686,723
|
154,016,519
|
5,146,784
|
741,917
|
(150,298,422
|
)
|
9,606,798
|
|||||||||||||||||
Issued pursuant to agency agreement
|
8,975,126
|
28,424,732
|
28,424,732
|
|||||||||||||||||||||
Warrant liability issued during the period
|
(11,509,338
|
)
|
(11,509,338
|
)
|
||||||||||||||||||||
Share issue expense
|
(1,546,800
|
)
|
(1,546,800
|
)
|
||||||||||||||||||||
Issued Other
|
7,500
|
66,234
|
66,234
|
|||||||||||||||||||||
Warrants exercised during the period
|
6,500
|
59,998
|
59,998
|
|||||||||||||||||||||
Warrants expired during the period
|
741,917
|
(741,917
|
)
|
-
|
||||||||||||||||||||
Stock based compensation
|
1,151,933
|
1,151,933
|
||||||||||||||||||||||
Net and Comprehensive loss for the period
|
(14,228,570
|
)
|
(14,228,570
|
)
|
||||||||||||||||||||
Balance - September 30, 2018
|
21,675,849
|
$
|
170,253,262
|
$
|
6,298,717
|
$
|
-
|
$
|
(164,526,992
|
)
|
$
|
12,024,987
|
||||||||||||
See notes to financial statements
|
TITAN MEDICAL INC.
|
||||||||||||||||||||
Unaudited Condensed Interim Statement of Net and Comprehensive Loss
|
||||||||||||||||||||
For the Three and Nine Months Ended September 30, 2018 and 2017
|
||||||||||||||||||||
(In U.S. Dollars)
|
||||||||||||||||||||
Three months ended
|
Nine months ended
|
|||||||||||||||||||
September 30,
|
September 30,
|
|||||||||||||||||||
|
Note
|
2018
|
2017
|
2018
|
2017
|
|||||||||||||||
Revenue:
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||||||||
Expenses:
|
||||||||||||||||||||
Amortization
|
5,371
|
2,527
|
22,485
|
13,312
|
||||||||||||||||
Consulting fees
|
134,009
|
132,753
|
505,197
|
403,186
|
||||||||||||||||
Stock based compensation
|
4(b)
|
|
428,528
|
400,892
|
1,151,933
|
1,024,574
|
||||||||||||||
Insurance
|
120,434
|
5,533
|
136,391
|
18,997
|
||||||||||||||||
Management salaries and fees
|
622,910
|
623,819
|
2,062,909
|
1,870,574
|
||||||||||||||||
Marketing and investor relations
|
55,395
|
77,479
|
226,393
|
243,316
|
||||||||||||||||
Office and general
|
110,106
|
55,060
|
344,733
|
222,561
|
||||||||||||||||
Professional fees
|
142,299
|
80,507
|
466,766
|
377,157
|
||||||||||||||||
Rent
|
23,602
|
26,974
|
73,395
|
77,228
|
||||||||||||||||
Research and Development
|
9,143,987
|
4,061,695
|
18,664,336
|
9,712,072
|
||||||||||||||||
Travel
|
64,430
|
67,251
|
250,327
|
224,627
|
||||||||||||||||
Foreign exchange (gain)/loss
|
286,152
|
194,157
|
(646,245
|
)
|
274,721
|
|||||||||||||||
11,137,223
|
5,728,647
|
23,258,620
|
14,462,325
|
|||||||||||||||||
Finance Income (cost):
|
||||||||||||||||||||
Interest
|
93,894
|
3,356
|
176,877
|
8,764
|
||||||||||||||||
Gain (Loss) on change in fair value of warrants
|
2(b), 5
|
|
4,075,833
|
(8,099,030
|
)
|
9,928,944
|
(5,726,557
|
)
|
||||||||||||
Warrant liability issue cost
|
(566,960
|
)
|
(78,496
|
)
|
(1,075,771
|
)
|
(576,886
|
)
|
||||||||||||
3,602,767
|
(8,174,170
|
)
|
9,030,050
|
(6,294,679
|
)
|
|||||||||||||||
Net and Comprehensive Loss
|
$
|
7,534,456
|
$
|
13,902,817
|
$
|
14,228,570
|
$
|
20,757,004
|
||||||||||||
Basic and Diluted Loss Per Share
|
$
|
0.41
|
$
|
1.65
|
$
|
0.95
|
$
|
3.05
|
||||||||||||
Weighted Average Number of Common Shares,
|
||||||||||||||||||||
Basic and Diluted
|
18,253,430
|
8,410,063
|
14,936,375
|
6,800,328
|
||||||||||||||||
See notes to financial statements
|
TITAN MEDICAL INC.
|
||||||||||||||||
Unaudited Condensed Interim Statements of Cash Flows
|
||||||||||||||||
For the Three and Nine Months Ended September 30, 2018 and 2017
|
||||||||||||||||
(In U.S. Dollars)
|
||||||||||||||||
Three months ending
|
Nine months ending
|
|||||||||||||||
September 30,
|
September 30,
|
|||||||||||||||
2018
|
2017
|
2018
|
2017
|
|||||||||||||
Cash provided by (used in):
|
||||||||||||||||
Operating activities:
|
||||||||||||||||
Net loss for the period
|
$
|
(7,534,456
|
)
|
$
|
(13,902,817
|
)
|
$
|
(14,228,570
|
)
|
$
|
(20,757,004
|
)
|
||||
Items not involving cash:
|
||||||||||||||||
Amortization
|
5,371
|
2,527
|
22,485
|
13,312
|
||||||||||||
Stock based compensation
|
428,528
|
400,892
|
1,151,933
|
1,024,574
|
||||||||||||
Other share compensation
|
-
|
-
|
66,234
|
-
|
||||||||||||
Warrant liability-fair value adjustment
|
(4,075,833
|
)
|
7,389,248
|
(9,928,944
|
)
|
5,016,775
|
||||||||||
Warrant liability-foreign exchange adjustment
|
283,894
|
170,553
|
(651,762
|
)
|
221,742
|
|||||||||||
Loss on extinquishment of other liabilities
|
-
|
709,782
|
-
|
709,782
|
||||||||||||
Changes in non-cash working capital items:
|
||||||||||||||||
Amounts receivable, prepaid expenses and deposits
|
(444,935
|
)
|
231,729
|
(2,263,365
|
)
|
(496,957
|
)
|
|||||||||
Accounts payable and accrued liabilities
|
250,756
|
(674,100
|
)
|
2,221,239
|
701,473
|
|||||||||||
Cash used in operating activities
|
(11,086,675
|
)
|
(5,672,186
|
)
|
(23,610,750
|
)
|
(13,566,303
|
)
|
||||||||
Financing activities:
|
||||||||||||||||
Net proceeds from issuance of common shares and warrants
|
18,051,242
|
3,719,490
|
26,908,982
|
14,220,805
|
||||||||||||
Cash provided by financing activities
|
18,051,242
|
3,719,490
|
26,908,982
|
14,220,805
|
||||||||||||
Investing Activities:
|
||||||||||||||||
Increase in furniture and equipment
|
-
|
-
|
-
|
(3,427
|
)
|
|||||||||||
Cost of Patents
|
(100,867
|
)
|
(81,943
|
)
|
(197,906
|
)
|
(187,267
|
)
|
||||||||
Cash used in investing activities
|
(100,867
|
)
|
(81,943
|
)
|
(197,906
|
)
|
(190,694
|
)
|
||||||||
Increase (decrease) in cash and cash equivalents
|
6,863,700
|
(2,034,639
|
)
|
3,100,326
|
463,808
|
|||||||||||
Cash and cash equivalents, beginning of period
|
22,367,119
|
6,838,358
|
26,130,493
|
4,339,911
|
||||||||||||
Cash and cash equivalents, end of period
|
$
|
29,230,819
|
$
|
4,803,719
|
$
|
29,230,819
|
$
|
4,803,719
|
||||||||
Cash and cash equivalents comprise:
|
||||||||||||||||
Cash
|
$
|
261,935
|
$
|
2,556,533
|
$
|
261,935
|
$
|
2,556,533
|
||||||||
Cash Equivalents
|
28,968,884
|
2,247,186
|
28,968,884
|
2,247,186
|
||||||||||||
$
|
29,230,819
|
$
|
4,803,719
|
$
|
29,230,819
|
$
|
4,803,719
|
|||||||||
See notes to financial statements
|
Cost
|
|||||
Balance at December 31, 2017
|
$
|
978,126
|
|||
Additions
|
197,906
|
||||
Balance at September 30, 2018
|
$
|
1,176,032
|
|||
Amortization
|
|||||
Balance at December 31, 2017
|
$
|
203,901
|
|||
Amortization for the period
|
15,771
|
||||
Balance at September 30, 2018
|
$
|
219,672
|
|||
Net Book Value
|
|||||
At December 31, 2017
|
$
|
774,225
|
|||
At September 30, 2018
|
$
|
956,360
|
a)
|
Authorized:
|
unlimited number of common shares, no par
|
|
||
Issued:
|
21,675,849 (December 31, 2017: 12,686,723)
|
Nine Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 30, 2018
|
September 30, 2017
|
|||||||||||||||
Number of
|
Weighted-average
|
Number of
|
Weighted-average
|
|||||||||||||
Stock Options
|
Exercise Price (CDN)
|
Stock Options
|
Exercise Price (CDN)
|
|||||||||||||
Balance Beginning
|
591,609
|
$
|
21.30
|
240,075
|
$
|
33.00
|
||||||||||
Granted
|
322,517
|
$
|
13.51
|
366,161
|
$
|
15.68
|
||||||||||
Expired/Forfeited
|
(23,765
|
)
|
$
|
17.36
|
(43,296
|
)
|
$
|
34.93
|
||||||||
Balance Ending
|
890,361
|
$
|
18.51
|
562,940
|
$
|
21.58
|
Options Outstanding | |||||||||||||
Weighted-average
|
|||||||||||||
Exercise
|
Number
|
remaining
|
Options
|
||||||||||
Price (CDN)
|
Outstanding
|
contractual life (years)
|
Exercisable
|
||||||||||
$3.28
|
31,498
|
6.92
|
31,498
|
||||||||||
$4.50
|
18,935
|
4.91
|
18,935
|
||||||||||
$4.80
|
3,040
|
1.96
|
3,040
|
||||||||||
$7.49
|
5,590
|
6.77
|
5,590
|
||||||||||
$9.00
|
11,481
|
6.77
|
11,481
|
||||||||||
$9.60
|
1,105
|
2.02
|
1,105
|
||||||||||
$11.70
|
6,667
|
2.18
|
3,333
|
||||||||||
$12.00
|
1,948
|
2.18
|
1,948
|
||||||||||
$12.90
|
50,000
|
5.55
|
12,500
|
||||||||||
$14.40
|
18,950
|
6.11
|
-
|
||||||||||
$15.00
|
16,667
|
5.36
|
4,167
|
||||||||||
$15.00
|
273,948
|
6.31
|
-
|
||||||||||
$17.10
|
277,519
|
5.30
|
69,380
|
||||||||||
$28.80
|
10,170
|
0.22
|
10,170
|
||||||||||
$30.00
|
105,719
|
2.90
|
81,462
|
||||||||||
$30.60
|
6,120
|
2.23
|
4,889
|
||||||||||
$32.40
|
18,810
|
2.33
|
18,810
|
||||||||||
$41.70
|
658
|
1.21
|
658
|
||||||||||
$45.30
|
560
|
1.87
|
560
|
||||||||||
$51.60
|
15,371
|
1.69
|
15,371
|
||||||||||
$52.80
|
3,537
|
0.43
|
3,537
|
||||||||||
$58.20
|
12,069
|
0.64
|
12,069
|
||||||||||
890,361
|
5.10
|
310,503
|
Grant date/Person entitled | Number of Options | Vesting Conditions | Contractual life of Options |
January 17, 2017, option grants to Employees
|
277,519
|
Vest as to ¼ of the total number of Options granted, every year from Option Date
|
7 years
|
February 7, 2017 option grants to Employees
|
16,667
|
Vest as to 1/4 of the total number of Options granted, every year from Option Date
|
7 years
|
April 17, 2017, option grants to Employees
|
50,000
|
Vest as to 1/4 of the total number of Options granted, every year from Option Date
|
7 years
|
September 7, 2017, options granted to Consultants
|
6,667
|
Half vest in 3 months and the remaining half in 6 months
|
3 years
|
September 7, 2017, options granted to Directors
|
12,269
|
immediately
|
7 years
|
September 15,2017, options granted to Consultants
|
3,040
|
immediately
|
3 years
|
October 6, 2017, options granted to Consultants
|
1,105
|
immediately
|
3 years
|
November 8, 2017 option grants to Employees
|
18,950
|
Vest as to 1/4 of the total number of Options granted, every year from Option Date
|
7 years
|
December 4, 2017, options granted to Consultants
|
1,948
|
immediately
|
3 years
|
December 4, 2017, options granted to Consultants
|
6,667
|
Half vest immediately and the remaining half in 12 months
|
3 years
|
January 19, 2018 option grants to Employees
|
273,948
|
Options will vest the earlier of commercialization or 3 years from grant date.
|
7 years
|
July 6, 2018, options granted to Directors
|
17,071
|
immediately
|
7 years
|
August 29, 2018, options granted to Directors
|
31,498
|
immediately
|
7 years
|
2018
|
2017
|
||
|
|||
Fair Value at grant date (CDN)
|
$1.44 - $ 7.50
|
$ 2.40 - $ 9.60
|
|
Share price at grant date (CDN)
|
$2.57 - $13.80
|
$ 4.50 - $16.20
|
|
Exercise price (CDN)
|
$3.28 - $15.00
|
$ 4.50 - $17.10
|
|
Expected Volatility
|
88.1% - 96%
|
82.4% - 83.3%
|
|
Option Life
|
3 years
|
3 - 4 years
|
|
Expected dividends
|
nil
|
nil
|
|
Risk-free interest rate
|
1.86% - 2.16%
|
0.89% - 1.63%
|
Nine Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 30, 2018
|
September 30, 2017
|
|||||||||||||||
Number of
|
Number of
|
|||||||||||||||
Warrants
|
Amount
|
Warrants
|
Amount
|
|||||||||||||
Opening Balance
|
5,260,705
|
$
|
741,917
|
5,651,434
|
$
|
855,800
|
||||||||||
Expired during the year
|
||||||||||||||||
Exercise Price CDN $1.25
|
||||||||||||||||
Expiry March 18, 2018
|
(5,260,705
|
)
|
(741,917
|
)
|
-
|
-
|
||||||||||
Expired during the year
|
||||||||||||||||
Exercise Price CDN $1.77
|
||||||||||||||||
Expiry March 14, 2017
|
-
|
-
|
(390,729
|
)
|
(113,883
|
)
|
||||||||||
Ending Balance
|
-
|
$
|
-
|
5,260,705
|
$
|
741,917
|
Nine Months Ended
|
Year Ended
|
|||||||||||||||
September 30, 2018
|
December 31, 2017
|
|||||||||||||||
Number of
|
Number of
|
|||||||||||||||
Warrants
|
Amount
|
Warrants
|
Amount
|
|||||||||||||
Opening Balance
|
4,933,231
|
$
|
17,849,460
|
2,581,703
|
$
|
2,365,691
|
||||||||||
Issue of warrants expiring, March 16, 2019
|
-
|
-
|
357,787
|
572,326
|
||||||||||||
Issue of warrants expiring, March 16, 2021
|
-
|
-
|
357,787
|
725,484
|
||||||||||||
Issue of warrants expiring, June 29, 2022
|
-
|
-
|
1,983,522
|
3,364,118
|
||||||||||||
Issue of warrants expiring, August 24, 2022
|
-
|
-
|
563,067
|
822,372
|
||||||||||||
Issue of warrants expiring, December 5, 2022
|
-
|
-
|
1,533,333
|
5,223,686
|
||||||||||||
Issue of warrants expiring, April 10, 2023
|
1,295,554
|
5,212,087
|
-
|
-
|
||||||||||||
Issue of warrants expiring, August 10, 2023
|
7,679,574
|
6,297,251
|
||||||||||||||
Warrants exercised during the year
|
(6,500
|
)
|
(28,949
|
)
|
(1,755,142
|
)
|
(7,953,581
|
)
|
||||||||
Warrants expired during the year
|
-
|
(688,826
|
)
|
-
|
||||||||||||
Foreign exhange adjustment during the year
|
(651,762
|
)
|
-
|
305,475
|
||||||||||||
Fair value adjustment during the year
|
(9,928,944
|
)
|
12,423,889
|
|||||||||||||
Ending Balance
|
13,901,859
|
$
|
18,749,143
|
4,933,231
|
$
|
17,849,460
|
September 30, 2018
|
December 31, 2017
|
|||||||||||||||
Number of Shares
|
%
|
Number of Shares
|
%
|
|||||||||||||
John Barker
|
23,714
|
0.11
|
23,714
|
0.19
|
||||||||||||
Martin Bernholtz
|
-
|
-
|
102,383
|
0.81
|
||||||||||||
David McNally
|
4,167
|
0.02
|
1,667
|
0.01
|
||||||||||||
Stephen Randall
|
18,243
|
0.08
|
11,910
|
0.09
|
||||||||||||
John Schellhorn
|
294
|
-
|
294
|
-
|
||||||||||||
Bruce Wolff
|
7,610
|
0.04
|
2,010
|
0.02
|
||||||||||||
Total
|
54,028
|
0.25
|
141,978
|
1.12
|
||||||||||||
Common Shares Outstanding
|
21,675,849
|
100
|
%
|
12,686,723
|
100
|
%
|
·
|
the Company is committed to developing its robotic surgical system with the objective of substantially improving upon minimally invasive surgery;
|
·
|
the Company intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures;
|
·
|
the SPORT Surgical System is being developed with the goal of inserting the interactive multi-articulating instruments and the 3D high definition vision system into the patient’s body cavity through a single incision;
|
·
|
our technology and research and development objectives and milestones, including such development milestones as completing the engineering confidence build and achieving design freeze, estimated costs, schedules for completion and probability of success;
|
·
|
our intention with respect to updating any forward-looking statement after the date on which such statement is made or to reflect the occurrence of unanticipated events;
|
·
|
our expectation with respect to continuing animal and human cadaver studies;
|
·
|
our expectation that we can in a timely manner produce the appropriate preclinical and clinical data required for our 510(k) application to the U.S. Food and Drug Administration, and Technical File for the CE Mark;
|
·
|
our expectation with respect to launching a commercial product in certain jurisdictions;
|
·
|
our intentions to develop a robust training curriculum and post-training assessment tools;
|
·
|
our plans to develop and commercialize the SPORT Surgical System and the estimated incremental costs (including the status, cost and timing of achieving the development milestones disclosed herein);
|
·
|
our plans to design, create and refine software for production system functionality of the SPORT Surgical System and the estimated incremental costs (including the status, cost and timing of achieving the development milestones disclosed herein);
|
·
|
our intentions to complete formative and summative human factors studies;
|
·
|
our belief that existing and planned prototype units will be suitable to support human factors studies, preclinical evaluation and activities related to securing confirmatory human data during the remainder of 2018 and in 2019;
|
·
|
our intentions with respect to initiating marketing activities following receipt of the applicable regulatory approvals;
|
·
|
our intention to continue to assess specialized skill and knowledge requirements and recruitment of qualified personnel and partners;
|
·
|
our belief that the materials and parts necessary for the manufacture of a clinical-grade SPORT Surgical System will be available in the marketplace;
|
·
|
our intended use of proceeds of any offering of our securities;
|
·
|
our intention with respect to not paying any cash dividends on Common Shares in the foreseeable future;
|
·
|
our intention to retain future earnings, if any, to finance expansion and growth;
|
·
|
our projected competitive conditions with respect to our products;
|
·
|
our technology and research and development objectives, including such development milestones as completing the engineering confidence build and achieving design freeze, estimated costs, schedules for completion and probability of success;
|
·
|
the Company continues to explore in-licensing opportunities for technologies that may be used in conjunction with the Company’s robotic surgical system;
|
·
|
the Company anticipates that it will continue its pursuit of key strategic relationships;
|
·
|
the Company’s continuing efforts to secure its intellectual property and expanding its patent portfolio by filing patent applications as it progresses in the development of robotic surgical technologies and by licensing suitable technologies;
|
·
|
the Company’s current plan is to focus on the development and commercialization of the SPORT Surgical System at estimated incremental costs and according to the timeline as set forth in the table below;
|
·
|
the Company has decided to build additional prototypes and develop more advanced instruments and training systems for expanded use for additional surgical procedures;
|
·
|
the Company intends to utilize a direct sales force and/or distribution partner(s) to initiate marketing the SPORT Surgical System to hospitals; and
|
·
|
the Company’s expectation that confirmatory human clinical data will be required for regulatory submissions.
|
|
•
|
Florida Hospital Nicholson Center in Celebration, Florida;
|
|
|
|
|
•
|
Columbia University Medical Center in New York, New York; and
|
|
|
|
|
•
|
Institut Hospitalo-Universitaire de Strasbourg (“IHU Strasbourg”) in Strasbourg, France.
|
1.
|
Multi-disciplinary applications of a new robotic platform by Barbara Seeliger, MD and Lee Swanstrom, MD (IHU Strasbourg), accepted and presented as a poster at the Society of American Gastrointestinal and Endoscopic Surgeons Meeting, Seattle, WA. (April 2018);
|
2.
|
Single-port prostatectomy using SPORT Surgical System by Eric Barret, MD (IMM, France), accepted and presented as a poster at the EAU Section of Urology Technology Meeting, Modena, Italy, (May 2018);
|
3.
|
Multispecialty single port robotic technology applied in the live animal model: proof of concept by Travis Rogers, MD, Eduardo Parra Davila, MD, Vipul Patel, MD (all from Florida Hospital), Ricardo Estape, MD (South Miami GOG) and Armando Melani, MD (IRCAD Brazil), accepted and presented as a poster at the Society of Robotic Surgery Meeting, Stockholm, Sweden (June 2018);
|
4.
|
Feasibility of single-port partial nephrectomy using SPORT surgical system by Eric Barret, MD (IMM, France), accepted and presented as a poster at Society of Robotic Surgery Meeting, Stockholm, Sweden (June 2018);
|
5.
|
Single-port robotic partial and hemi nephrectomy using a novel single port robotic platform by Sebastien Crouzet, MD (University of Lyon, France) and Barbara Seeliger, MD (IHU Strasbourg), accepted and presented at EAU Robotic Urology Section Meeting, Marseille, France (September 2018);
|
6.
|
Reverse Objective Structured Assessment of Technical Skills (Reverse-OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles by Chetna Arora, MD, Arnold P. Advincula, MD (both from Columbia University Medical Center) and William B. Burke, MD (Stony Brook Cancer Center), accepted and presented at Society of European Robotic Gynecologic Surgeons Meeting, Milan, Italy (September 2018);
|
7.
|
Multispecialty single port robotic technology applied in the live animal model: proof of concept by Travis Rogers, MD, Eduardo Parra Davila, MD, Vipul Patel, MD (all from Florida Hospital), Ricardo Estape, MD (South Miami GOG) and Armando Melani, MD (IRCAD Brazil), accepted and presented at World Congress of Endourology Meeting, Paris, France (September 2018); and
|
8.
|
Reverse Objective Structured Assessment of Technical Skills (Reverse-OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles by Chetna Arora, MD, Arnold P. Advincula, MD (both from Columbia University Medical Center) and William B. Burke, MD (Stony Brook Cancer Center), accepted at American Association of Gynecologic Laparoscopists World Congress, Las Vegas, NV (November 2018).
|
Research and Development
Expenditures
|
Three Months Ended
September 30, 2018
|
Nine Months Ended
September 30, 2018
|
Three Months Ended
September 30, 2017
|
Nine Months Ended
September 30, 2017
|
Intellectual property development
License and royalties
Product development
|
$2,327
-
9,141,660
|
$12,212
-
18,652,124
|
$5,000
-
4,056,695
|
$15,000
5,000
9,692,072
|
Total
|
$9,143,987
|
$18,664,336
|
$4,061,695
|
$9,712,072
|
Three
Months
Ended
September
30, 2018
|
Three
Months
Ended
June 30,
2018
|
Three
Months
Ended
March 31,
2018
|
Three
Months
Ended
December
31, 2017
|
Three
Months
Ended
September
30, 2017
|
Three
Months
Ended
June 30,
2017
|
Three
Months
Ended
March 31,
2017
|
Three
Months
Ended
December
31, 2016
|
|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net and
Comprehensive Loss (gain) from
operations
|
$7,534,456
|
$5,885,415
|
$808,699
|
$12,829,980
|
$13,902,817
|
$1,865,913
|
$4,988,274
|
$2,008,365
|
Basic and
diluted loss per
share
|
$0.41
|
$0.47
|
$0.07
|
$1.20
|
$1.80
|
$0.30
|
$0.90
|
$0.30
|
Issue Date
|
Expiry Date
|
Number
Issued
|
Number
Outstanding
|
Exercise
Price
(CDN $)
|
Potential
Proceeds
(CDN $)
|
|
TMD.WT.F
|
November 16, 2015
|
November 16, 2020
|
233,740
|
233,740
|
$48.00
|
11,219,520
|
TMD.WT.G
|
February 12, 2016
|
February 12, 2021
|
389,027
|
386,694
|
$30.00
|
11,600,820
|
TMD.WT.G
|
February 23, 2016
|
February 12, 2021
|
58,226
|
58,226
|
$30.00
|
1,746,780
|
TMD.WT.H
|
March 31, 2016
|
March 31, 2021
|
501,831
|
501,831
|
$36.00
|
18,065,916
|
TMD.WT.H
|
April 14, 2016
|
March 31, 2021
|
75,275
|
75,275
|
$36.00
|
2,709,900
|
TMD.WT.I
|
September 20, 2016
|
September 20, 2021
|
569,444
|
569,444
|
$22.50
|
12,812,490
|
TMD.WT.I
|
October 27, 2016
|
September 20, 2021
|
67,667
|
67,667
|
$22.50
|
1,522,508
|
NOT LISTED
|
March 16, 2017
|
March 16, 2019
|
357,787
|
135,824
|
$12.00
|
1,629,888
|
NOT LISTED
|
March 16, 2017
|
March 16, 2021
|
357,787
|
355,253
|
$15.00
|
5,328,795
|
NOT LISTED
|
June 29, 2017
|
June 29, 2022
|
1,612,955
|
75,810
|
$6.00
|
454,860
|
NOT LISTED
|
July 21, 2017
|
June 29, 2022
|
370,567
|
370,567
|
$6.00
|
2,223,402
|
NOT LISTED
|
August 24, 2017
|
August 24, 2022
|
563,067
|
563,067
|
$6.00
|
3,378,402
|
NOT LISTED
|
December 5, 2017
|
December 5, 2022
|
1,533,333
|
1,533,333
|
$18.00
|
27,599,994
|
NOT LISTED
|
April 10, 2018
|
April 10, 2023
|
1,126,665
|
1,126,665
|
$10.50
|
11,829,983
|
NOT LISTED
|
May 10, 2018
|
April 10, 2023
|
168,889
|
168,889
|
$10.50
|
1,773,335
|
*NOT LISTED
|
August 10, 2018
|
August 10, 2023
|
7,679,574
|
7,679,574
|
$4.15
|
31,870,232
|
TOTAL
|
15,665,834
|
13,901,859
|
145,766,825
|
Milestone Number
|
Development Milestones
|
Estimated
Cost (in U.S.
million $)
|
Schedule for
Milestone
Completion
|
Comments
|
Milestone 1
|
Prototype, test and procure surgeon feedback on revised workstation controls
Complete software and hardware change requirements and finalize computer and software architecture for production systems
Complete revisions to instrument and lens wash system and demonstrate performance
|
Q2 2018
|
Completed
|
|
Milestone 2
|
Complete Camera Insertion Tube (CIT) engineering confidence build based on improved design
Complete design of SPORT Surgical System surgeon workstation and patient cart for engineering confidence build
Complete and demonstrate full suite of simulation software for beta test
|
Q3 2018
|
Completed
|
|
Milestone 3
|
Complete SPORT Surgical System capital equipment engineering confidence build based on improved design
|
13.6 (1)
|
Q4 2018
|
|
Milestone 4
|
Document results of confidence build unit testing, implement subsystem design improvements and schedule preliminary audit of quality system by European Notified Body
|
14.2(2)
|
Q1 2019
|
|
Milestone 5
|
Update system design and related hardware and software documentation
|
14.4(3)
|
Q2 2019
|
|
Submit draft protocols to FDA in Q-submission(s) for comment
|
Completed
|
|||
Milestone 6
Milestone 7
|
Initiate SPORT Surgical System Design Freeze
Verify production system operation with clinical experts under rigorous formal (summative) human factors evaluation under simulated robotic manipulation exercises and through exercises of the completed surgeon simulation software and training program
Complete and document preclinical live animal (swine), cadaver surgery and human confirmatory studies according to final protocols for FDA submittal
Obtain ISO 13485 Certification
Submit technical file to European Notified Body for review for CE Mark
Submit 510(k) application to FDA
|
14.3(4)
13.4(5)
|
Q3 2019 –
Q4 2019
|
|
TOTAL
|
69.9
|
(1) |
Includes research and development costs estimated at approximately US $12.4 million, and general and administrative costs estimated at approximately US $1.2 million.
|
(2) |
Includes research and development costs estimated at approximately US $12.7 million, and general and administrative costs estimated at approximately US $1.5 million.
|
(3) |
Includes research and development costs estimated at approximately US $13.0 million, and general and administrative costs estimated at approximately US $1.4 million.
|
(4) |
Includes research and development costs estimated at approximately US $12.8 million, and general and administrative costs estimated at approximately US $1.5 million.
|
(5) |
Includes research and development costs estimated at approximately US $11.9 million, and general and administrative costs estimated at approximately US $1.5 million.
|
Type of Securities
|
Number of Common Shares issued or issuable
upon conversion
|
Common Shares
|
21,675,849
|
Stock options(1)
|
890,361
|
Warrants
|
13,901,859
|
Broker warrants(2)
|
790,920
|
(1) |
The Company has outstanding options enabling certain employees, directors, officers and consultants to purchase Common Shares. Please refer to note 4(b) of the Interim Financial Statements for terms of such options.
|
(2) |
Pursuant to the agency agreement in respect of the March 2017 offering, in addition to the cash commission paid to the agents, 50,005 broker warrants were issued to the agents. Each broker warrant entitles the holder thereof to acquire one Common Share at the price of CDN $10.50 for a period of 24 months following the closing date.
|
(a)
|
Stock Options
|
(b)
|
Warrant Liability
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Titan Medical Inc. (the “issuer”) for the interim period ended September 30, 2018.
|
2. |
No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specifiedin securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
|
5.1 |
Control framework: The control framework the issuer’s other certifying officer and I used to design the issuer’s ICFR is Integrated Framework (COSO).
|
5.2 |
ICFR – material weakness relating to design: N/A
|
5.3 |
Limitation on scope of design: N/A
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on January 1, 2018 and ended on September 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.
|
David McNally
Chief Executive Officer
Titan Medical Inc.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Titan Medical Inc. (the “issuer”) for the interim period ended September 30, 2018.
|
2. |
No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specifiedin securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
|
5.1 |
Control framework: The control framework the issuer’s other certifying officer and I used to design the issuer’s ICFR is Integrated Framework (COSO).
|
5.2 |
ICFR – material weakness relating to design: N/A
|
5.3 |
Limitation on scope of design: N/A
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on January 1, 2018 and ended on September 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.
|
Stephen D. Randall
Chief Financial Officer
Titan Medical Inc.
|